PDSB News and Press, PDS Biotechnology Corporation From 09/06/23

PRINCETON, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s prop...

PRINCETON, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s prop...

PRINCETON, N.J., Aug. 16, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s propr...

2023-08-14 11:52:10 ET PDS Biotechnology Corporation (PDSB) Q2 2023 Earnings Conference Call August 14, 2023 8:00 am ET Company Participants Frank Bedu-Addo - Chief Executive Officer Lauren Wood - Chief Medical Officer Matthew Hill - Chief Financial Officer G...

2023-08-14 09:26:13 ET More on PDS Biotech PDS Biotechnology: Interim Data Reinforces Push Towards Phase 3 Study The Prognosis For PDS Biotechnology PDS Biotechnology: Promising Interim HNSCC Data Reaffirms Investment Prospects PDS Biotech meets efficacy thre...

2023-08-14 07:37:15 ET PDS Biotechnology press release ( NASDAQ: PDSB ): Q2 GAAP EPS of -$0.37 misses by $0.02 . Cash and cash equivalents as of June 30, 2023, totaled approximately $60.6 million. Based on the company’s cash resources, PDS Biotech believes this ...

Successful submission of final clinical protocol and supporting CMC information to FDA to initiate Phase 3 VERSATILE-003 trial in the fourth quarter 2023 Biomarker data from VERSATILE-002 to be presented at ESMO 2023 Company to host conference call and webcast today at 8:00 AM E...

VERSATILE-003 will evaluate PDS0101 in combination with KEYTRUDA ® in recurrent or metastatic HPV16-positive head and neck cancer PDS Biotech anticipates initiating the VERSATILE-003 trial in the fourth quarter of 2023 PRINCETON, N.J., Aug. 14, 2023 (GLOBE NEWSWIRE) -- PD...

2023-08-14 00:22:02 ET Summary PDS Biotechnology has achieved positive results in its phase 2 study of PDS0101 in combination with Merck's Keytruda for HPV16-positive head and neck cancer. The interim analysis showed 9 confirmed responses, which increased to 14 in a later update, ...

2023-08-13 05:30:32 ET Summary PDS Biotechnology Corporation has had a volatile stock performance in recent years. The company has made slow and steady progress advancing its pipeline and is well-liked within the analyst firm community. With two registrational studies on the h...